Discover
UNCY
Unicycive Therapeutics, Inc.
5.28
2 x 3.76
2 x 5.73
bid
ask
+
0.59
12.58%
2 @ 04:00 PM
5.28 +0.00 (0.00%)
| Ytd | -8.49% | |
| 1y | 13.79% |
4.45
day range
5.30
3.71
52 week range
8.74
| Open | 4.57 | Prev Close | 4.69 | Low | 4.45 | High | 5.30 | Mkt Cap | 144.64M |
| Vol | 6.02M | Avg Vol | 1.30M | EPS | -2.25 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 7.47 | 200-d Avg | 6.26 | 1yr Est | 5.50 |
| Income Statement | |||
| Operating Expenses | 8.44M | ||
| Research and Development Expense | 1.61M | ||
| Selling, General and Administrative Expense | 6.83M | ||
| Operating Income | -8.44M | ||
| Net Income | -12.82M | ||
| Net Income Common Stock | -12.82M | ||
| Net Income Common Stock (USD) | -12.82M | ||
| Consolidated Income | -12.82M | ||
| Earnings per Basic Share | -0.54 | ||
| Earnings per Basic Share (USD) | -0.54 | ||
| Earnings per Diluted Share | -0.54 | ||
| Earning Before Interest & Taxes (EBIT) | -12.82M | ||
| Earning Before Interest & Taxes (USD) | -12.82M | ||
| Weighted Average Shares | 23.91M | ||
| Weighted Average Shares Diluted | 23.91M | ||
| Balance Sheet | |||
| Cash and Equivalents | 37.37M | ||
| Cash and Equivalents (USD) | 37.37M | ||
| Investments | 17.22M | ||
| Investments Current | 17.22M | ||
| Current Assets | 63.55M | ||
| Property, Plant & Equipment Net | 861.00K | ||
| Total Assets | 64.41M | ||
| Debt Current | 598.00K | ||
| Total Debt | 815.00K | ||
| Current Liabilities | 26.49M | ||
| Debt Non-Current | 217.00K | ||
| Total Liabilities | 26.70M | ||
| Accumulated Retained Earnings (Deficit) | -140.65M | ||
| Accumulated Other Comprehensive Income | 6.00K | ||
| Shareholders Equity | 37.70M | ||
| Shareholders Equity (USD) | 37.70M | ||
| Assets Non-Current | 861.00K | ||
| Total Debt (USD) | 815.00K | ||
| Liabilities Non-Current | 217.00K | ||
| Trade and Non-Trade Payables | 1.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 211.00K | ||
| Net Cash Flow from Financing | 19.57M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.17M | ||
| Capital Expenditure | -8.00K | ||
| Issuance (Purchase) of Equity Shares | 19.57M | ||
| Net Cash Flow from Investing | -5.15M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -5.15M | ||
| Net Cash Flow from Operations | -6.24M | ||
| Share Based Compensation | 754.00K | ||